Oct 21, 2019 - AstraZeneca's (AZN) third-quarter result is expected to reflect the impact of new drug sales.
Jul 30, 2019 - Another busy day awaits investors here in the middle of summer: U.S.-China trade talks resume, Personal Income & Spending data is out and Q2 earnings continue their torrent.
Aug 30, 2019 - IDMC recommends termination of AbbVie's (ABBV) late-stage study on its small cell lung cancer candidate, Rova-T. AbbVie discontinues development.
Sep 05, 2019 - Merck's (MRK) label expansion application for Keytruda in combination with Pfizer's Inlyta for the first-line treatment of renal cell carcinoma gets approval in Europe.
Sep 06, 2019 - The latest EU nod makes Roche's (RHHBY) immuno-oncology drug -- Tecentriq -- the first and only cancer immunotherapy approved for the initial treatment of ES-SCLC in Europe.
Sep 06, 2019 - Bristol-Myers (BMY) announces dismal results from a late-stage study on its immuno-oncology drug Opdivo for critical brain tumor.
Sep 06, 2019 - Allergan (AGN) settles with two Ohio plaintiffs for $5 million. Merck's (MRK) Keytruda, Roche's (RHHBY) Tecentriq and J&J's (JNJ) Stelara get EU approval for expanded use.
Sep 09, 2019 - Lilly (LLY) presents data from the LIBRETTO-001 study on selpercatinib for the treatment of RET fusion-positive non-small cell lung cancer. The candidate as a monotherapy attains 68% ORR.
Sep 12, 2019 - Roche's (RHHBY) immuno-oncology drug, Tecentriq, meets the primary goal in a late-stage study in NSCLC patients. Also, the company reports positive data on its MS drug in a phase III study.
Sep 13, 2019 - Roche's (RHHBY) immuno-oncology drug, Tecentriq, meets the primary goal in a late-stage study in NSCLC patients. Also, the company reports positive data on its NMOSD drug in a phase III study.